RESEARCH HUB

The science behind every compound, in one place.

A searchable scientific reference for the full catalogue — separate from the shop, built for evaluating evidence before you buy. Filter by research category or by how mature the evidence is.

4
Established Elsewhere
30
Emerging Human Research
0
Preclinical / Early
EVIDENCE
CATEGORY
34 of 34 compounds
Emerging Human Research
SKIN & HAIR

GLOW

GHK-Cu / BPC-157 / TB-500 blend

Current literature on GLOW is summarized by its studied mechanism: gHK-Cu is investigated for stimulating collagen and extracellular-matrix protein synthesis and for supporting microcirculation; BPC-157 is studied for angiogenic signaling, fibroblast migration, and anti-inflammatory cytokine modulation; TB-500 is investigated for actin-regulated cell migration that supports angiogenesis and tissue turnover. The three mechanisms are studied together for a combined effect on regeneration that exceeds what any single component shows in isolation in the published literature. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
SKIN & HAIR

KLOW

GHK-Cu / BPC-157 / TB-500 / Kojic Acid blend

Current literature on KLOW is summarized by its studied mechanism: combines the copper-tripeptide and repair-fragment activity studied under GLOW with kojic acid's investigated effect on melanin synthesis pathways via tyrosinase inhibition, examined in protocols that pair pigmentation and dermal-remodeling endpoints in the same model. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
RECOVERY & REPAIR

BPC-157 + TB-500

Body Protection Compound-157 / Thymosin Beta-4 fragment

Current literature on BPC-157 + TB-500 is summarized by its studied mechanism: bPC-157 (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) is studied for VEGF-driven angiogenesis and endothelial proliferation, fibroblast/collagen signaling, and modulation of pro-inflammatory cytokines (TNF-α, IL-6). TB-500 (a thymosin beta-4 fragment) is studied for actin-cytoskeleton-driven endothelial and fibroblast migration and reduced neutrophil activation. In combination, research examines whether BPC-157's angiogenic/protective signaling and TB-500's migration/fibrosis-reduction activity produce a broader recovery effect than either studied alone — including in fracture-healing models, where the pairing has been examined for callus formation and mineralization alongside reduced fibrosis. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
METABOLIC HEALTH

5-AMINO-1MQ

5-amino-1-methylquinolinium

Current literature on 5-AMINO-1MQ is summarized by its studied mechanism: investigated for inhibiting NNMT, an enzyme that methylates nicotinamide and is implicated in regulating cellular NAD+/SAM metabolism within adipose tissue. Research examines whether NNMT inhibition increases NAD+ availability for mitochondrial processes, which is studied downstream for effects on lipolysis and energy partitioning without the catabolic muscle-wasting effect associated with some other metabolic-research compounds. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
RECOVERY & REPAIR

ARA-290

Cibinetide

Current literature on ARA-290 is summarized by its studied mechanism: studied as a selective agonist of the innate repair receptor (a receptor complex distinct from the classical EPO receptor), investigated for modulating immune-cell inflammatory-cytokine output, supporting nerve-fiber and endothelial repair signaling, and — in preclinical models — for pain-related nerve-signaling research, without producing the erythrocytosis associated with full-length EPO. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
HORMONAL SUPPORT

CJC-1295 (No DAC) + Ipamorelin

GHRH(1-29) analog / selective GHRP

Current literature on CJC-1295 (No DAC) + Ipamorelin is summarized by its studied mechanism: cJC-1295 (No DAC) is studied as a GHRH-receptor agonist that stimulates the pituitary's natural GH secretion machinery, with published research literature centered on GH/IGF-1 axis activity, body composition, and metabolic signaling. Ipamorelin is investigated as a highly selective ghrelin-receptor (GHS-R) agonist, noted in research literature for stimulating GH release with comparatively minimal effect on cortisol or prolactin relative to older-generation secretagogues. The pairing is studied for combined, more pronounced pulsatile GH signaling than either compound alone. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
COGNITIVE SUPPORT

DSIP

Delta Sleep-Inducing Peptide

Current literature on DSIP is summarized by its studied mechanism: investigated for modulating delta-wave EEG activity associated with deep sleep phases, for reducing hypothalamic-pituitary-adrenal (HPA) axis activity and cortisol output under research stress models, and for influencing melatonin secretion and circadian-rhythm regulation. Separately studied for immunomodulatory and neuro-restorative signaling relevant to central-nervous-system recovery research, though its precise receptor-level mechanism remains an open research question — part of why it continues to be actively studied. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
LONGEVITY

Epitalon

Epithalon (Ala-Glu-Asp-Gly tetrapeptide)

Current literature on Epitalon is summarized by its studied mechanism: investigated for stimulating telomerase activity and supporting telomere restoration in select cell models — the basis for its 'anti-aging' research classification — and for normalizing melatonin secretion patterns and sleep/wake cycles via pineal-gland signaling pathways. Separately studied for immunomodulatory effects and for supporting normal function of cardiovascular, endocrine, and hepatic tissue in aging-research models. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
LONGEVITY

FOXO4-DRI

FOXO4-p53 interfering peptide

Current literature on FOXO4-DRI is summarized by its studied mechanism: investigated for selectively interfering with FOXO4 binding to p53 specifically within senescent cells — cells that have stopped dividing but resist apoptosis and accumulate with age, contributing to tissue dysfunction (the 'senescence-associated secretory phenotype' studied in aging literature). By disrupting this interaction, research examines whether p53 is freed to trigger apoptosis selectively in senescent cells while sparing healthy dividing cells, a mechanism studied as 'senolytic' (senescent-cell-clearing) rather than broadly cytotoxic. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
SKIN & HAIR

GHK-Cu

Glycyl-L-Histidyl-L-Lysine copper complex

Current literature on GHK-Cu is summarized by its studied mechanism: studied for facilitating copper delivery to extracellular-matrix remodeling enzymes, stimulating collagen and elastin synthesis, and improving hydration and barrier signaling in dermal-research models. Separately investigated for activating hair-follicle signaling and improving scalp microcirculation in hair-research models, and for antioxidant/anti-inflammatory activity via free-radical neutralization and cytokine modulation. Research literature reports collagen-synthesis increases on the order of ~70% in cited in-vitro/ex-vivo work. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
IMMUNE SUPPORT

Glutathione

L-γ-glutamyl-L-cysteinyl-glycine

Current literature on Glutathione is summarized by its studied mechanism: investigated as the primary intracellular antioxidant, neutralizing reactive oxygen species and protecting DNA and proteins from oxidative damage. Studied for phase-II liver detoxification pathways (clearance of xenobiotics, heavy metals, and metabolic byproducts) and for supporting leukocyte function in immune-research models. Separately investigated in pigmentation research for reducing melanin synthesis, and in cardiovascular research for vascular-elasticity and inflammatory-marker effects. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
HORMONAL SUPPORT

HCG (5000 IU)

Human Chorionic Gonadotropin

Current literature on HCG (5000 IU) is summarized by its studied mechanism: investigated for agonism at the LH receptor on gonadal tissue, studied in models of testicular and ovarian steroidogenesis (testosterone and progesterone/estrogen synthesis pathways) and hypothalamic-pituitary-gonadal (HPG) axis research. Because its LH-receptor activity is far longer-lasting than endogenous LH's pulsatile signaling, research literature specifically studies it as a tool for sustained gonadal-axis stimulation in endocrinology models, including research on testicular-function maintenance and gonadal-tissue signaling independent of pituitary output. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
BODY COMPOSITION

IGF-1 LR3

Long R3 Insulin-like Growth Factor 1

Current literature on IGF-1 LR3 is summarized by its studied mechanism: investigated as an IGF-1 receptor agonist with substantially prolonged research half-life relative to native IGF-1 — because it evades sequestration by IGF-binding proteins (IGFBPs) that normally limit native IGF-1's circulating activity. Studied in models of myoblast (muscle precursor cell) proliferation and differentiation, protein-synthesis signaling via the PI3K/Akt/mTOR pathway, and — separately — in metabolic research given IGF-1's structural and receptor overlap with insulin signaling. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
HORMONAL SUPPORT

Ipamorelin

Selective growth hormone secretagogue pentapeptide

Current literature on Ipamorelin is summarized by its studied mechanism: investigated as a selective agonist of the growth hormone secretagogue receptor (GHS-R) in the pituitary, studied for stimulating pulsatile growth hormone release that, in cited research, shows comparatively limited effect on cortisol or prolactin relative to earlier secretagogues — a selectivity profile studied as reducing off-target hormonal research variables. Downstream GH/IGF-1 activity is studied for effects on protein synthesis, lipolysis, and tissue-repair signaling. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
HORMONAL SUPPORT

Kisspeptin

Kisspeptin-10 (KP-10)

Current literature on Kisspeptin is summarized by its studied mechanism: investigated as an agonist of the KISS1 receptor (GPR54) on GnRH neurons, studied for triggering pulsatile GnRH release that in turn drives pituitary LH/FSH secretion. Research on this pathway is considered central to understanding puberty onset, reproductive-axis regulation, and — in more recent literature — energy-balance/metabolic crosstalk with reproductive signaling, since kisspeptin neurons are also studied for sensitivity to metabolic status. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
COSMETIC PEPTIDES

Melanotan II

Melanotan-II (MT-II)

Current literature on Melanotan II is summarized by its studied mechanism: investigated as a non-selective melanocortin receptor agonist (activating both MC1R and MC4R), studied for stimulating melanogenesis — melanin production in skin melanocytes — via MC1R, and separately for MC4R-mediated central effects on appetite regulation and sexual-behavior/libido pathways in preclinical models. Its non-selective binding profile is precisely why research literature spans both dermatological/pigmentation and behavioral-neuroendocrine domains. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
LONGEVITY

NAD+

Nicotinamide Adenine Dinucleotide

Current literature on NAD+ is summarized by its studied mechanism: investigated for its role as an electron carrier in the mitochondrial electron-transport chain (critical for ATP production) and as a required substrate for sirtuin and PARP enzyme families implicated in DNA repair and cellular-aging regulation. Because NAD+ degrades relatively quickly once in aqueous solution, research protocols typically account for limited post-reconstitution stability. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
COGNITIVE SUPPORT

Pinealon

Glu-Asp-Arg tripeptide bioregulator

Current literature on Pinealon is summarized by its studied mechanism: investigated for gene-expression modulating activity relevant to neuronal protein synthesis (including FKBP1B and PPAR-alpha/gamma expression studied in the literature), for protecting dendritic spine structure under oxidative neural stress, and for supporting short-term memory, attention, and learning-speed research endpoints. Separately studied for stimulating melatonin synthesis relevant to sleep-phase research, and for cardiovascular research markers such as exercise heart-rate response. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
HORMONAL SUPPORT

PT-141

Bremelanotide

Current literature on PT-141 is summarized by its studied mechanism: investigated as an MC4R-predominant agonist acting on central-nervous-system melanocortin receptors, studied for effects on sexual arousal and libido pathways that are distinct from — and studied with less crossover into — the peripheral MC1R-driven pigmentation effects seen with less-selective melanocortin compounds like Melanotan II. Research literature covers both male and female sexual-response models. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
COGNITIVE SUPPORT

Selank

Tuftsin analog heptapeptide

Current literature on Selank is summarized by its studied mechanism: investigated for modulation of GABAergic and monoaminergic (serotonin/dopamine) neurotransmitter activity underlying its studied anxiolytic effect, alongside effects on BDNF expression relevant to memory and learning-speed research. Separately studied for supporting immune function and general resistance to infection — a research thread stemming from its tuftsin-derived origin — and for sleep-quality research endpoints. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
COGNITIVE SUPPORT

Semax

ACTH(4-10) analog heptapeptide

Current literature on Semax is summarized by its studied mechanism: investigated for upregulating BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) expression, and for modulating monoaminergic (dopamine/serotonin) and cholinergic signaling implicated in attention and memory-consolidation research. Studied in models of ischemic neuroprotection (research on stroke-recovery models originating in Russian clinical research), attention/focus research, and — separately — in visual-system research given documented effects on retinal signaling in some cited literature. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
HORMONAL SUPPORT

Sermorelin

GHRH(1-29) analog

Current literature on Sermorelin is summarized by its studied mechanism: investigated as a GHRH-receptor agonist on the pituitary, studied for stimulating endogenous growth-hormone release in a manner that preserves the body's natural pulsatile secretion pattern and physiological negative-feedback regulation — a distinction researchers draw against exogenous GH administration, which bypasses the pituitary entirely. Research literature centers on pituitary-reserve testing (used diagnostically in some contexts to assess pituitary GH-secretion capacity) and on aging-related decline in GHRH signaling. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
COSMETIC PEPTIDES

SNAP-8

Acetyl octapeptide-3

Current literature on SNAP-8 is summarized by its studied mechanism: investigated for competitively inhibiting SNARE complex formation (the vesicle-fusion machinery involved in neurotransmitter release) at the neuromuscular junction, studied in topical research models for reducing the frequency and intensity of expression-related muscle micro-contractions responsible for dynamic wrinkle formation. Research literature specifically studies its topical activity relative to injectable SNARE-inhibiting compounds, given its inability to cross the skin barrier to the same depth. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
MITOCHONDRIAL FUNCTION

SS-31

Elamipretide

Current literature on SS-31 is summarized by its studied mechanism: investigated for binding and stabilizing cardiolipin in the inner mitochondrial membrane, which is studied for reducing reactive oxygen species (ROS) production, improving mitochondrial respiration and ATP output, and exerting anti-inflammatory and cardioprotective signaling. This cardiolipin-specific targeting is what distinguishes it in the literature from generalized antioxidant compounds. Research spans cardiology (ischemia/reperfusion protection), neurology (neurodegenerative-disease models), nephrology (kidney-function research), and broader metabolic-disorder research. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Established Elsewhere
IMMUNE SUPPORT

Thymosin Alpha-1

Thymalfasin

Current literature on Thymosin Alpha-1 is summarized by its studied mechanism: investigated for modulating T-cell maturation and function via toll-like receptor and dendritic-cell signaling pathways, studied for enhancing antibody production and natural-killer-cell activity in immune-response research models. The published literature includes antiviral research (studied alongside chronic viral-infection models), oncology-adjunct research (studied as a complement to immunotherapy protocols), and autoimmune/inflammatory research — all framed in the literature as areas of active study, not established outcomes for this research-use listing. Evidence strength varies by research area — one area is tied to an indication already approved elsewhere, which is unusually mature for this class, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
IMMUNE SUPPORT

VIP

Vasoactive Intestinal Peptide

Current literature on VIP is summarized by its studied mechanism: investigated as an agonist of VPAC1/VPAC2 receptors, studied for reducing pro-inflammatory cytokines (IL-6, TNF-α) relevant to autoimmune and inflammatory research models, for bronchial smooth-muscle relaxation relevant to respiratory research, for neuroprotective/neuroregenerative signaling studied in neurodegenerative-research literature, for vasodilation and microcirculation research, and for gastric-secretion and gut-motility research given its GI-tract distribution. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
IMMUNE SUPPORT

Thymalin

Thymic polypeptide bioregulator complex

Current literature on Thymalin is summarized by its studied mechanism: investigated for supporting T-lymphocyte differentiation and maturation in the thymus, for normalizing CD4/CD8 T-cell ratios studied in age-related immune decline models, and for modulating cellular immunity broadly. As a multi-component polypeptide extract rather than an isolated single molecule, research on Thymalin studies its aggregate bioregulatory effect on thymic tissue rather than a single well-defined receptor mechanism — an important distinction from single-sequence peptides like Thymosin Alpha-1. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
MITOCHONDRIAL FUNCTION

MOTS-c

Mitochondrial-derived peptide, 12S rRNA-encoded

Current literature on MOTS-c is summarized by its studied mechanism: investigated for activating the AMPK metabolic pathway, studied for improving insulin sensitivity and glucose uptake, and for supporting fatty-acid metabolism and energy-expenditure research relevant to mitochondrial-nuclear communication. As an exercise-responsive peptide, research also examines its levels changing with physical activity, linking it to exercise-physiology and physical-performance research models. Broader research also studies antioxidant and anti-inflammatory activity attributed to improved mitochondrial efficiency. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
IMMUNE SUPPORT

KPV

Lysine-Proline-Valine (α-MSH C-terminal tripeptide)

Current literature on KPV is summarized by its studied mechanism: investigated for suppressing NF-κB pathway activation and downstream pro-inflammatory cytokine production, studied extensively in gut-barrier and intestinal-inflammation research models (including research on maintaining epithelial tight-junction integrity), and separately in dermal-inflammation and wound-model research. Because it retains anti-inflammatory activity from the parent alpha-MSH sequence while lacking affinity for the pigmentation-driving MC1R pathway, it is studied as a way to isolate melanocortin-linked anti-inflammatory signaling from cosmetic pigmentation effects. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
RECOVERY & REPAIR

BPC-157

Body Protection Compound-157

Current literature on BPC-157 is summarized by its studied mechanism: investigated for promoting angiogenesis via VEGF/VEGFR2 pathway activation and endothelial proliferation, for stimulating fibroblast migration and collagen synthesis relevant to tendon/ligament/muscle repair, and for modulating pro-inflammatory cytokines (TNF-α, IL-6). Separately studied for gastric- and intestinal-mucosa protective signaling (its original research context), for peripheral-nerve regeneration research, and — in fracture-research models — for supporting bone-callus formation and mineralization. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Emerging Human Research
RECOVERY & REPAIR

TB-500

Thymosin Beta-4 fragment (17 amino acids)

Current literature on TB-500 is summarized by its studied mechanism: investigated for sequestering G-actin to promote directional cell migration, stimulating angiogenesis, and reducing fibrosis in models of muscle, tendon, and ligament repair. Research also studies reduced neutrophil activation contributing to its anti-inflammatory profile, and — in fracture-research models — a role in reducing fibrotic scarring alongside stimulated cell migration into the injury site. Evidence strength varies by research area — most findings remain in the emerging or preclinical stage, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Established Elsewhere
METABOLIC HEALTH

Semaglutide

GLP-1 receptor agonist analog

Current literature on Semaglutide is summarized by its studied mechanism: investigated as a GLP-1 receptor agonist, studied for enhancing glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and modulating hypothalamic appetite signaling in metabolic research models. Broader research literature also studies cardiovascular endpoints (blood-pressure and lipid-profile research), pancreatic β-cell protective signaling, and early-stage cognitive-research questions connected to diabetes-related cognitive decline. Evidence strength varies by research area — one area is tied to an indication already approved elsewhere, which is unusually mature for this class, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Established Elsewhere
METABOLIC HEALTH

Tirzepatide

GIP/GLP-1 dual receptor agonist analog

Current literature on Tirzepatide is summarized by its studied mechanism: investigated for simultaneous GIP- and GLP-1-receptor agonism, studied for synergistic effects on insulin secretion, glucagon suppression, gastric-emptying delay, and lipolysis stimulation in adipose tissue in metabolic research models. Broader research studies cardiovascular endpoints (blood pressure, lipid profile), anti-inflammatory markers relevant to metabolic syndrome, and early-stage neuroprotective-research questions. Evidence strength varies by research area — one area is tied to an indication already approved elsewhere, which is unusually mature for this class, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→
Established Elsewhere
METABOLIC HEALTH

Retatrutide

GIP/GLP-1/Glucagon triple receptor agonist analog

Current literature on Retatrutide is summarized by its studied mechanism: investigated for combined incretin (GIP/GLP-1) and glucagon-receptor agonism, studied for effects on energy expenditure (via glucagon-receptor-driven lipolysis) layered on top of the appetite-suppression and glucose-regulating pathways studied for dual agonists. Broader research also studies cardiovascular endpoints (cholesterol, triglycerides, blood pressure) and anti-inflammatory/neuroprotective markers. Evidence strength varies by research area — one area is tied to an indication already approved elsewhere, which is unusually mature for this class, and unanswered questions center on long-term, high-dose, and combination-protocol effects that fall outside the scope of published studies to date. Researchers should weigh evidence strength per claim rather than treating the compound's overall research interest as uniform.

Read Full Profile→